Pfizer

Pharmaceuticals
PFE
$ 44 (1.1)%
Share price
$ 247 bn
Market Cap
$ 255 bn
Enterprise Value

Carbon footprint

4.6 Ton
GHG emissions per $ 1 mln investment
0.12x the weighted average for S&P 500
FY2021
How is this calculated?
-0.8%
YOY change in GHG emissions
Weaker than the +4.9% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-4.6%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

Pfizer aims to reduce Scope 1 + 2 by 46% by 2030 from a base year 2019


1.5°C
Pfizer's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Pfizer's GHG emissions (market-based) (Kt of CO2e)
Pfizer's Carbon intensity (Tons per 1 USDm)

Pfizer's carbon footprint

Pfizer reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 1,172 Kt (-10 /-0.8% y-o-y). Also positively, carbon intensity tumbled to 14 t (-14 /-49.3% y-o-y).

Pfizer's Scope 3 emissions plummeted to 3,818 Kt (-1,890 /-33.1% y-o-y). There has been no consistent trend in recent years.

The company is committed to reducing Scope 1 + 2 by 46% by 2030 from a base year 2019, which translates into the estimated reduction of -54 Kt per annum over the period of FY2022 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Pfizer aims to achive carbon neutrality across its operations (Scope 1 + 2) in 2030. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.

Company environmental metrics

Show more...